Guo et al. [172] found that FGF19 can ameliorate obesity-induced bone loss caused by activating the Wnt/β-catenin signaling pathway, promoting osteoblast differentiation, and inhibiting osteoclastogenesis through osteopontin. This evidence concerns the gene FGF19 and obesity due to melanocortin 4 receptor deficiency.